Effects of C-4 stereochemistry and C-4′ hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues

被引:63
作者
Bergeron, RJ [1 ]
Wiegand, J
McManis, JS
McCosar, BH
Weimar, WR
Brittenham, GM
Smith, RE
机构
[1] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA
[2] Columbia Univ Coll Phys & Surg, Dept Pediat, Div Hematol, New York, NY 10032 USA
关键词
D O I
10.1021/jm990058s
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Additional structure-activity studies of desferrithiocin analogues are carried out. The effects of stereochemistry at C-4 on the ligands' iron clearing efficiency are reviewed and assessed using the enantiomers 4,5-dihydro-2-(2,4-dihydroxyphenyl)thiazole-4(R)-carboxylic acid and 4,5-dihydro-2-(2,4-dihydroxyphenyl)thiazole-4(S)-carboxylic acid. The utility of 4'-hydroxylation as a method of reducing the toxicity of desazadesferrithiocin analogues is also examined further with the synthesis and in vivo comparison of 4,5-dihydro-2-(2-hydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid, which is the natural product 4-methylaeruginoic acid, and 4,5-dihydro-2-(2,4- dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid. The stereochemistry at C-4 is shown to have a substantial effect on the iron clearing efficiency of desferrithiocin analogues, as does C-4'-hydroxylation on the toxicity profile. All of the compounds are evaluated in a bile-duct-cannulated rodent model to determine iron clearance efficiency and are carried forward to the iron-overloaded primate for iron clearing measurements. On the basis of the results of the present work, although 4,5-dihydro-2-(2,4-dihydroxyphenyl)thiazole-4(S)-carboxylic acid is still the most promising candidate for clinical evaluation, 4,5-dihydro-2-(2,4- dihydroxyphenyl)-4-methylthiazole-4(S)- carboxylic acid (4'-hydroxydesazadesferrithiocin) also merits further preclinical assessment.
引用
收藏
页码:2432 / 2440
页数:9
相关论文
共 26 条
[1]  
AKSOY M, 1984, HYPERTENSION IRON CH, P11
[2]   HYDROXAMATKOMPLEXE .3. EISEN(III)-AUSTAUSCH ZWISCHEN SIDERAMINEN UND KOMPLEXONEN - DISKUSSION DER BILDUNGSKONSTANTEN DER HYDROXAMATKOMPLEXE [J].
ANDEREGG, G ;
LEPLATTE.F ;
SCHWARZENBACH, G .
HELVETICA CHIMICA ACTA, 1963, 46 (04) :1409-&
[3]   METAL-COMPLEX FORMATION OF A NEW SIDEROPHORE DESFERRITHIOCIN AND OF 3 RELATED LIGANDS [J].
ANDEREGG, G ;
RABER, M .
JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1990, (17) :1194-1196
[4]  
BERGERON RJ, 1990, ANN NY ACAD SCI, V612, P378
[5]  
BERGERON RJ, 1993, BLOOD, V81, P2166
[6]   The origin of the differences in (R)- and (S)-desmethyldesferrithiocin - Iron-clearing properties [J].
Bergeron, RJ ;
Wiegand, J ;
Ratliff-Thompson, K ;
Weimar, WR .
COOLEYS ANEMIA: SEVENTH SYMPOSIUM, 1998, 850 :202-216
[7]   THE DESFERRITHIOCIN PHARMACOPHORE [J].
BERGERON, RJ ;
LIU, CZ ;
MCMANIS, JS ;
XIA, MXB ;
ALGEE, SE ;
WIEGAND, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (10) :1411-1417
[8]  
BERGERON RJ, 1992, BLOOD, V79, P1882
[9]   HBED: A potential alternative to deferoxamine for iron-chelating therapy [J].
Bergeron, RJ ;
Wiegand, J ;
Brittenham, GM .
BLOOD, 1998, 91 (04) :1446-1452
[10]   Desazadesmethyldesferrithiocin analogues as orally effective iron chelators [J].
Bergeron, RJ ;
Wiegand, J ;
Weimar, WR ;
Vinson, JRT ;
Bussenius, J ;
Yao, GW ;
McManis, JS .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (01) :95-108